Medical weight loss. In Pittsburgh's North Hills.

Average weight loss in clinical trials varies by medication and individual. Semaglutide trials (the STEP studies) showed an average of approximately 15 percent body weight reduction at 68 weeks for patients who completed the protocol. Tirzepatide trials (the SURMOUNT studies) showed approximately 20 percent at 72 weeks. Individual results vary, and your actual result depends on how consistently you take it, dosing, baseline metabolic health, and lifestyle factors. We track body composition during treatment rather than scale weight alone, so the picture reflects what is actually shifting.

Both are used for chronic weight management and work by signaling satiety and slowing gastric emptying. Tirzepatide adds a second receptor activation (GIP) that has shown greater average weight loss in clinical trials. Semaglutide has been in clinical use longer and is well-characterized. The right choice depends on your medical history, prior medication response, insurance considerations, and goals. Melissa makes this recommendation at consultation after reviewing your labs and history.

The most common side effects are gastrointestinal: nausea, occasional vomiting, diarrhea or constipation, and reduced appetite (which is part of the mechanism, not a complication). Side effects are typically most pronounced in the first one to two weeks after each dose increase and generally diminish with continued use at a steady dose. Conservative starting doses and slow titration significantly reduce side-effect severity. Rare but serious risks include pancreatitis and gallbladder considerations; we screen for these in your baseline labs and monitor throughout.

Most patients stay on a GLP-1 medication for at least twelve to eighteen months to reach and stabilize at their goal. Some patients continue indefinitely at a maintenance dose to keep their results; some taper off after eighteen to twenty-four months with continued lifestyle and peptide support. The decision is collaborative and based on your individual response, side effects, and long-term goals. We do not push you to continue or to stop on an arbitrary timeline.

Significant weight loss reduces facial fat pads in the midface, temples, and lower face, and can lead to skin laxity considerations wherever the underlying volume has shifted faster than the skin can remodel. This is anatomy, not a side effect of the medication. At Aetheria that can include Sculptra for facial volume, Morpheus8 for skin tone, and QuantumRF for contour. The conversation typically begins around month four to six of active loss. Many patients begin Sculptra or Morpheus8 in the later phases of active weight loss or shortly after stabilizing; QuantumRF contouring is usually timed for when you are close to the weight you mean to keep.

Yes. Many patients begin in-person clinical care after starting GLP-1 therapy. The first visit covers baseline labs, body composition, current dose and tolerance, side-effect history, and what you are looking for from ongoing care. From there the plan is yours: continue your current dose with in-person follow-up, taper into maintenance, or adjust based on what the labs show. The medication is one tool in a broader Metabolic Health plan, and the plan is built around your situation.

Yes, and you don't have to move your prescription to do it. Bring your current medication, dose, and any labs, and Melissa plans the aesthetic side in person: which layer is involved, which of Sculptra, Morpheus8, or QuantumRF fits it, and when to start based on your weight trend. If you'd rather have the GLP-1 care handled in person as well, that's available in the same room, with labs, body composition, and titration alongside the plan.

The layer decides the tool. Hollowing at the cheeks, temples, or lower face is usually a Sculptra conversation. Skin tone, texture, and early laxity on the face, neck, or body is where Morpheus8 starts. A pocket of fat under the chin or along the jaw is QuantumRF's job: fat-side, where Morpheus8 is skin-side. The order follows your trend. Sculptra and Morpheus8 can begin in the later phases of active loss; QuantumRF waits until you're close to the weight you mean to keep. If skin excess is beyond what energy-based treatment is designed for, the personalized plan says so instead of proposing a series. Individual results vary.

There's no universal number. The conversation usually opens around month four to six of active loss, once your trend is visible, and the timing is set from that trend rather than a template. Sculptra and Morpheus8 have a wider window. QuantumRF is contouring rather than a weight-loss tool, so it's planned for a body that's close to settled. Individual results vary.

At Aetheria, yes. Every program starts with an in-person consultation of about 60 minutes, where Melissa reviews your medical history and any labs you already have, and we may ask for bloodwork before a first dose. Check-ins during titration are in person too, so she can adjust your dose based on how you're tolerating it.

At Aetheria Aesthetics & Wellness in Ross Township, in Pittsburgh's North Hills. Melissa Kolowitz, PA-C, prescribes and manages semaglutide and tirzepatide herself, and decides with you at an in-person consultation whether a GLP-1 fits and which one. Aetheria serves patients across the North Hills, Allegheny County, and surrounding areas, from our studio at Ross Park Mall. Many come from Ross Township, Wexford, Cranberry Township, Sewickley, and Mars.